Pagas, Rodrigo S.
HRN: 24-78-11 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/02/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
04/02/2025
04/08/2025
IV
675mg
Q24
Impending Acute Respiratory Failuresec To CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes